Lazertinib
Lazertinib (YH25448) is a potent, irreversible, and orally bioavailable third-generation EGFR tyrosine kinase inhibitor with high selectivity for mutant EGFRs. It effectively targets EGFR mutations including L858R/T790M, Del19/T790M, and Del19 with IC50 values of 1.7, 2, and 3.3 nM, respectively, while sparing wild-type EGFR and other ErbB family members. Lazertinib crosses the blood-brain barrier and reduces tumor volume in EGFRT790M mutant NSCLC xenograft models, making it suitable for research in non-small cell lung cancer. Reagent grade, for research use only.

-
Catalog:
BP-43658
-
Name:
Lazertinib
-
Formula:
C30H34N8O3
-
MW:
554.7
-
CAS:
1903008-80-9
-
Purity:
-
Ships Within:
24 Hours
-
Storage Condition:
-20°C
-
Shipping:
Ambient Temperature
-
NMR:
View
-
SDS:
Inquire about MSDS